Citigroup Inc Sorrento Therapeutics, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.74 - $1.83 $572,598 - $1.42 Million	-773,782 Reduced 28.7%	1,922,143 $1.71 Million
Q3 2022 Nov 10, 2022	BUY	$1.51 - $2.88 $1.38 Million - $2.64 Million	915,370 Added 51.41%	2,695,925 $4.23 Million
Q2 2022 Aug 10, 2022	BUY	$1.24 - $2.33 $1.66 Million - $3.13 Million	1,341,465 Added 305.51%	1,780,555 $3.58 Million
Q1 2022 May 12, 2022	SELL	$2.0 - $4.9 $653,998 - $1.6 Million	-326,999 Reduced 42.68%	439,090 $1.02 Million
Q4 2021 Feb 10, 2022	BUY	$4.65 - $7.23 $1.93 Million - $3 Million	415,130 Added 118.28%	766,089 $3.56 Million
Q3 2021 Nov 10, 2021	BUY	$7.41 - $10.99 $2.6 Million - $3.86 Million	350,959 New	350,959 $2.68 Million

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.